Iovance Biotherapeutics, Inc. (IOVA) financial statements (2022 and earlier)

Company profile

Business Address 999 SKYWAY ROAD
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:504635307386145167104
Cash and cash equivalents7867148214510714
Short-term investments426562293  6070
Other undisclosed cash, cash equivalents, and short-term investments 6 304 020
Other undisclosed current assets41989430
Total current assets:508636316475149170104
Noncurrent Assets
Operating lease, right-of-use asset695511
Property, plant and equipment1015993222
Long-term investments and receivables92      
Long-term investments92      
Other noncurrent assets213334  
Other undisclosed noncurrent assets665    
Total noncurrent assets:269132285622
TOTAL ASSETS:777768345481155172106
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities844932141052
Accounts payable2714163111
Accrued liabilities57351612941
Debt  7    
Due to related parties      0
Other undisclosed current liabilities56     
Total current liabilities:895539141052
Noncurrent Liabilities
Long-term debt and lease obligation66454    
Long-term debt, excluding current maturities1      
Operating lease, liability65454
Liabilities, other than long-term debt 1220   
Deferred rent credit   0
Other liabilities 122    
Other undisclosed noncurrent liabilities(65)      
Total noncurrent liabilities:665770   
Total liabilities:15611246151052
Stockholders' equity
Stockholders' equity attributable to parent, including:622656299466145167104
Common stock 000000
Additional paid in capital1,7951,487869839395324208
Accumulated other comprehensive income (loss)(1)00(0) 00
Accumulated deficit(1,172)(830)(571)(373)(249)(157)(104)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:622656299466145167104
TOTAL LIABILITIES AND EQUITY:777768345481155172106

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:      (4)
Operating expenses(343)(262)(207)(128)(93)(54)(28)
Other undisclosed operating income      4
Operating loss:(343)(262)(207)(128)(93)(54)(28)
Nonoperating income0295110
Investment income, nonoperating029511 
Other nonoperating income      0
Net loss attributable to parent:(342)(260)(198)(124)(92)(53)(28)
Preferred stock dividends and other adjustments     (49) 
Net loss available to common stockholders, diluted:(342)(260)(198)(124)(92)(102)(28)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(342)(260)(198)(124)(92)(53)(28)
Comprehensive loss:(342)(260)(198)(124)(92)(53)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(0)0(0)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(343)(260)(197)(124)(92)(53)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: